RAB, member RAS oncogene family like 6Genealiases: C9orf86 · PARF · RBEL1 · pp8875
Q-omics provides the consensus-scored RABL6 profile across patient tissues and cancer cell-line models. RABL6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RABL6 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RABL6 RNA expression shows 18,337 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RABL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABL6 survival associations across molecular data types. RABL6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABL6 RNA expression–survival associations across cancer types. High RABL6 expression shows unfavorable associations in ACC, LIHC, KIRC, MESO and UCS, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RABL6 RNA expression.
This table summarizes RABL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RABL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABL6 shows higher tumor expression in COAD, LIHC, STAD, HNSC, UCEC and BRCA. The COAD box plot shows higher RABL6 RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with RABL6 in patient tissues and cancer cell lines. In patient samples, RABL6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RABL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
